002675 Yantai Dongcheng Biochemicals
- 12.44
- +0.16+1.30%
Yantai Dongcheng Biochemicals News
Express News | 58 stocks received financing buy-in of over 100 million yuan, kweichow moutai received a buy-in of 845 million yuan and ranked top.
Express News | Yantai Dongcheng Biochemicals has added a production center for nuclear medicine in Anhui.
Yantai Dongcheng Biochemicals (002675.SZ) equity distribution for 2023: 1.25 yuan per 10 shares.
Yantai Dongcheng Biochemicals (002675.SZ) has announced the equity distribution plan for 2023: based on the existing total share capital of the company, a cash dividend of RMB 1.25 per 10 shares will be distributed to all shareholders. The equity distribution registration date is June 21, 2024 and the ex-dividend date is June 24, 2024.
Yantai Dongcheng Biochemicals (002675.SZ): The operation of Hefei nuclear medicine production center has been put into operation.
Yantai Dongcheng Biochemicals (002675.SZ) announced that the company has received a research and development project from its wholly-owned subsidiary, Nanjing Jiangyuan Andyco Electronic Technology.
Dongcheng Pharmaceutical (002675): A leader in the nuclear medicine industry, innovative assets lead value reshaping
Dongcheng Pharmaceutical's transformation has become a leader in the domestic nuclear medicine industry. The company was founded in 1998 and officially entered the nuclear medicine field through the strategic acquisition of Chengdu Yunke Pharmaceutical in 2015. According to the company's financial report, the company has successive mergers and acquisitions since 2015
Pharmaceutical stocks generally strengthened. Taiji Group rose more than 5%, while Brother Technology, Donga Ejiao, China Resources 39, and Dongcheng Pharmaceutical had the highest gains.
Pharmaceutical stocks generally strengthened. Taiji Group rose more than 5%, while Brother Technology, Donga Ejiao, China Resources 39, and Dongcheng Pharmaceutical had the highest gains.
Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug
Dongcheng Pharmaceutical (002675.SZ): Clinical trial application approved for ¹ Lu-LNC1010 injection
Dongcheng Pharmaceutical (002675.SZ) issued an announcement that the company's holding subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (...
Express News | Dongcheng Pharmaceutical: Holding subsidiary approved for drug clinical trials
Express News | Dongcheng Pharmaceutical: APN-1607 obtained US FDA Fast Track Qualification
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Hebei Andike, a subsidiary of Dongcheng Pharmaceutical (002675.SZ), was recognized as a specialized, special and new small and medium-sized enterprise in Hebei Province
Dongcheng Pharmaceutical (002675.SZ) announced that the company's subsidiary, Hebei Andikezheng Electronics Technology Co., Ltd. (abbreviation...
US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection
Dongcheng Pharmaceutical (002675) Company Brief Review Report: Multiple Factors Influence Short-Term Performance, Steady Progress in Innovative Nuclear Drug Research and Development
Incident: The company released its 2023 annual report. In 2023, it achieved operating income of 3.276 billion yuan (-8.58%), net profit to mother was 210 million yuan (-31.75%), and net profit after deducting non-return to mother was 2.12 billion yuan
Dongcheng Pharmaceutical (002675): Heparin API cycle fluctuations and collection affect current performance, nuclear drug innovation and upgrading can be expected in the future
Incident: The company released its 2023 annual report, achieving operating income of 3.276 billion yuan, -8.58%; net profit to mother of 210 million yuan, or -31.75% year on year; net profit after deducting non-return to mother of 212 million yuan, year-on-year
Express News | Dongcheng Pharmaceutical: Subsidiary company 18F-LNC1007 injection obtained drug clinical trial approval notice
Dongcheng Pharmaceutical (002675): Performance fluctuations due to heparin APIs, innovative nuclear drugs are expected to reap
The 2023 results are lower than our expectations. The company announced the results for the first quarter of 2023 and 2024: in 2023, the company's revenue was 3.28 billion yuan, down 8.6% year on year, in line with our expectations; net profit due to mother 2.1
Dongcheng Pharmaceutical (002675): Heparin business disrupts performance testing and has a rich layout of nuclear drugs
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved revenue of 3.276 billion yuan, a year-on-year decrease of 8.58%, and achieved net profit of 210 million yuan to mother, a year-on-year decrease of 31.75%.
Dongcheng Pharmaceutical (002675): Heparin volume and price has bottomed out and is expected to resume its leading position in the nuclear drug layout in the country
Performance summary: The company achieved operating income of 3.276 billion yuan (-8.58%) for the full year of 2023; net profit of 210 million yuan (-31.75%) to mother, after deducting non-net profit of 212 million yuan (-26.17%)
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug
Analysis
Price Target
No Data
